Core Viewpoint - PAG has achieved significant returns from its investment in Boryu Biotech, marking a successful exit in the Chinese private equity market with a transaction valued at approximately $6.8 billion, the largest of its kind in history [5][6][19]. Investment Performance - PAG's investment in Boryu Biotech has yielded around 3 billion yuan in returns over approximately 39 months, with the firm holding a 44.62% stake valued at over 6 billion yuan prior to the company's IPO [6][21][22]. - The investment strategy included acquiring shares from the parent company, Haizheng Pharmaceutical, and additional funding rounds, leading to a total investment exceeding 4.1 billion yuan [10][19]. Company Growth and Development - Boryu Biotech was established as a strategic response to Haizheng Pharmaceutical's restructuring efforts in 2019, focusing on monoclonal antibody drugs and securing PAG as a key investor [10][11]. - The company has rapidly expanded its product pipeline in immunotherapy, achieving over 1 billion yuan in profit within nine months and projecting revenues to grow from approximately 1.257 billion yuan in 2023 to 1.623 billion yuan in 2024 [13][16]. Market Position and Future Prospects - Boryu Biotech has established itself as a leading player in the immunotherapy sector, with a strong sales and marketing team covering over 4,000 hospitals and 2,000 retail pharmacies in China [15]. - The company has a robust patent portfolio with 43 granted patents and 63 pending applications, enhancing its competitive edge in the market [15]. - Following its IPO, Boryu Biotech is expected to raise additional funds for operations and product development, further solidifying its market position [16][23].

中国科学院武汉病毒研究所发文，发现WV116对尼帕病毒的高效抑制活性(国际期刊EmergingMicrobes&Infections) 。 中国科学院武汉病毒研究所发文，发现WV116对尼帕病毒的高效抑制活性(国际期刊EmergingMicrobes&Infections) 。 关注： WV116(氢溴酸氘瑞米德韦片) 君实生物 海正药业 富祥药业 ...

Group 1 - The company’s subsidiary, Zhejiang Haizheng Pharmaceutical (Hangzhou) Co., Ltd., has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for injectable Micafungin, allowing it to produce and sell the product in the U.S. market [1][2] - The drug Micafungin is indicated for the treatment of candidemia, acute disseminated candidiasis, candidal peritonitis, and abscesses in adults and pediatric patients aged 4 months and older, as well as for the prevention of fungal infections in hematopoietic stem cell transplant patients [1] - The global sales of injectable Micafungin are projected to be approximately $208.33 million in 2024, with U.S. sales estimated at around $67.57 million [1] Group 2 - The company has invested approximately 17.94 million RMB in the development of injectable Micafungin [2]

Q&A 请介绍一下中国目前处方粮市场的基本情况，包括市场规模和增长情况，以及 猫狗市场的细分情况。 处方粮在国内和国际上都属于技术壁垒较高的品类。目前在国内，皇家是处方 粮市场的领军品牌，年销售规模约为 8 至 10 亿元（出厂价）。其他品牌如爱 迪生主打中药，年营收约 5,000 至 8,000 万元；广州傲龙主要通过互联网销售， 年营收约 5,000 万至 1 亿元；冠能也有跟进，但其品类较少，只有 6 至 8 个单 品，而皇家 SKU 数已突破 40 个。总体来看，中国处方粮市场规模大约在 15 至 20 亿元左右，相比整个宠物食品行业，这一数字仍然很小。 中国与国际市场相比，在处方粮领域有哪些差距？ 在国际市场上，如玛氏、皇家、高露洁等品牌的处方粮占据了很大的份额，并 且对利润贡献显著。例如玛氏集团 80%的宠物护理净利润来源于处方粮。而在 功能粮与处方粮的区别在于使用场景和目的，功能粮用于长期慢性病管 理或健康维护，而处方粮主要用于特定疾病治疗，功能粮市场潜力巨大， 但存在概念滥用问题。 传统宠物食品赛道竞争激烈，功能粮和处方粮因研发壁垒较高，将有助 于提升头部企业的市场集中度，并推动行业朝着更健康 ...

Core Viewpoint - The approval of the abbreviated new drug application (ANDA) for injectable micafungin by the U.S. FDA allows the company to produce and sell the product in the U.S. market [1] Group 1: Company Announcement - The company’s wholly-owned subsidiary, Zhejiang Hisun Pharmaceutical Co., Ltd. (referred to as "Hisun Hangzhou"), has received notification from the U.S. FDA regarding the approval of its ANDA for injectable micafungin [1] - This approval signifies a significant milestone for Hisun Hangzhou, enabling it to enter the U.S. market with this product [1] Group 2: Product Indications - Injectable micafungin is indicated for the treatment of: 1. Candidemia, acute disseminated candidiasis, candidal peritonitis, and abscesses in adults and pediatric patients aged 4 months and older 2. Candidemia, acute disseminated candidiasis, candidal peritonitis, and abscesses in pediatric patients under 4 months (without meningitis and/or ocular dissemination) 3. Esophageal candidiasis in adults and pediatric patients aged 4 months and older 4. Prevention of candidal infections in adults and pediatric patients aged 4 months and older following hematopoietic stem cell transplantation [1]

格隆汇1月23日丨海正药业(600267.SH)公布，公司全资子公司海正药业（杭州）有限公司（称"海正杭 州公司"）收到美国食品药品监督管理局（称"美国FDA"）的通知，海正杭州公司向美国FDA申报的注 射用米卡芬净的新药简略申请（ANDA，即美国仿制药申请）已获得批准，意味着海正杭州公司可以生 产并在美国市场销售该产品。 注射用米卡芬净适用于治疗：（1）成人和4个月及以上儿科患者的念珠菌血症、急性播散性念珠菌病、 念珠菌性腹膜炎及脓肿；（2）4个月以下儿科患者的念珠菌血症、急性播散性念珠菌病、念珠菌性腹膜 炎及脓肿（不伴有脑膜脑炎和/或眼部播散）；（3）成人和4个月及以上儿科患者的食管念珠菌病； （4）预防成人和4个月及以上儿科患者造血干细胞移植后的念珠菌感染。 ...

Core Viewpoint - Haizheng Pharmaceutical's wholly-owned subsidiary, Haizheng Hangzhou, has received FDA approval for the abbreviated new drug application of injectable micafungin, allowing production and sales in the U.S. [1] Group 1: Product Details - The approved drug is available in two specifications: 50mg and 100mg, and is indicated for the treatment and prevention of various candidiasis infections [1] - The global sales forecast for 2024 is approximately $208 million, with the U.S. market contributing about $67.57 million [1] - For the period from January to September 2025, global sales are projected to be around $143 million, with U.S. sales estimated at $46.23 million [1] Group 2: Investment and Financials - The company has invested approximately 17.94 million yuan in this project [1]

证券代码：600267 证券简称：海正药业 公告编号：临 2026-07 号 注射用米卡芬净适用于治疗：（1）成人和 4 个月及以上儿科患者的念珠菌血 症、急性播散性念珠菌病、念珠菌性腹膜炎及脓肿；（2）4 个月以下儿科患者的 念珠菌血症、急性播散性念珠菌病、念珠菌性腹膜炎及脓肿（不伴有脑膜脑炎和 /或眼部播散）；（3）成人和 4 个月及以上儿科患者的食管念珠菌病；（4）预防成 人和 4 个月及以上儿科患者造血干细胞移植后的念珠菌感染。原研药 Mycamine for Injection 由 Astellas Pharma US，Inc.公司研发，国内外生产、销售厂商主要有 SANDOZ、FRESENIUS、HIKMA PHARMA、浙江海正药业股份有限公司等。 据统计，注射用米卡芬净 2024 年全球销售额约 20,833.43 万美元，其中美国市场 销售额约 6,757.14 万美元；2025 年 1-9 月全球销售额约 14,340.18 万美元，其中 美国市场销售额约 4,623.39 万美元（数据来源于 IQVIA 数据库）。 海正杭州公司于 2024 年 9 月就注射用米卡芬净（50mg 和 10 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 来源：环球网 【环球网综合报道】2026年1月16日，上海证券交易所对浙江海正药业股份有限公司（简称：海正药 业）及6名相关责任人进行了通报批评，原因是该公司在2021年至2024年的年度报告中存在财务信息不 真实、不准确的问题。与此同时，浙江证监局也向海正药业出具了警示函，并将相关责任人记入证券期 货市场诚信档案。 上海证券交易所《纪律处分决定书》指出，经查明，海正药业于2025年8月26日披露《关于前期会计差 错更正的公告》，对2021—2024年年度报告的部分财务数据进行更正，其中涉及营业收入、营业成本以 及投资收益等科目。上述事项反映出海正药业此前披露的相关报告财务信息不真实、不准确。 《关于前期会计差错更正的公告》显示，2021—2023年，海正药业全资子公司浙江省医药工业有限公司 （以下简称"省医药公司"）部分原料贸易业务缺乏充分的商业实质及商业合理性，不满足收入确定的条 件，相应形成的重要前期差错更正涉及合计调减2021—2023年合并财务报表营业收入94882.64万元，调 减营业成本93002.88万元，调增投资收益1879.77万元；调增2 ...

Core Viewpoint - Recently, Zhejiang Hai Zheng Pharmaceutical Co., Ltd. announced corrections to its financial data for the years 2021 to 2024, indicating that previously disclosed financial information was inaccurate and untruthful [1] Group 1: Financial Corrections - The company corrected financial data related to operating revenue, operating costs, and investment income for the years 2021 to 2024 [1] - The announcement was made on August 26, 2025, highlighting the discrepancies in the annual reports [1] Group 2: Accountability and Penalties - The Shanghai Stock Exchange decided to publicly criticize the company and the responsible individuals, including the former chairman and other executives [1] - The penalties will be reported to the China Securities Regulatory Commission and recorded in the securities and futures market integrity database [1] - The company is required to submit a rectification report signed by all directors and senior management within one month of receiving the decision [1]